NEUBASE THERAPEUTICS INC (NBSE)

US64132K2015 - Common Stock

0.378  -0.01 (-3.2%)

After market: 0.42 +0.04 (+11.11%)

Unregistered users can only see 4 years or quarters

Examples of complete financials are available for MSFT and AAPL.

Please register or login for additional data.

TTM
(2023-9-30)
2022
(2022-9-30)
2021
(2021-9-30)
2020
(2020-9-30)
2019
(2019-9-30)
Revenue
0.000.000.000.000.00
Operating Expenses
13.38M33.32M26.57M17.07M25.51M
Research and Development
4.26M21.45M14.36M6.95M16.41M
Selling, General, and Administrative Expenses
9.12M11.87M12.20M10.12M9.10M
Operating Income
-13.38M-33.32M-26.57M-17.07M-25.51M
Interest Income/Expense
610.00K-290.00K-240.00K-270.00K-130.00K
Other Income/Expense
950.00K-170.00K1.40M-40.00K-490.00K
Non Recurring Items
-1.88M-650.00KN/AN/AN/A
Income Before Taxes
-13.73M-33.78M-25.41M-17.38M-26.13M
Income Tax
N/AN/AN/A0.000.00
Net Income
-13.73M-33.78M-25.41M-17.38M-26.13M
EBITDA
-13.44M-32.55M-26.17M-16.79M-25.38M
 
Per Share Data
EPS Diluted Total Ops
-7.79-20.85-18.54-17.72-63.73
Non GAAP EPS
-11.44-16.24-0.92-0.89N/A
 
Statistics

All data in USD

Charts